Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02289209 · ClinicalTrials.gov registry record · Phase 2
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
A Phase 2 study, sponsored by Dan Zandberg.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02289209 is a Phase 2 study that has completed, run by Dan Zandberg. The registered enrollment target is 48 participants.
The verdict
NCT02289209, a Phase 2 study, has completed, sponsored by Dan Zandberg.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab, trade name Keytruda®).
Interventions
- RADIATION Reirradiation
- DRUG MK-3475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02289209
The ClinicalTrials.gov registry entry for NCT02289209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dan Zandberg, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Reirradiation is the first listed.
NCT02289209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02289209 about?
NCT02289209 is a clinical study titled "Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck". Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab, trade name Keytruda®).
What is the current status of trial NCT02289209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2016-03-09. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT02289209?
The interventions under investigation include: Reirradiation (RADIATION), MK-3475 (DRUG).
Who is sponsoring clinical trial NCT02289209?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.